Pirtobrutinib CAS 2101700-15-4

Product Description:

Product Name: Pirtobrutinib CAS 2101700-15-4

Synonyms:

(S)-5-amino-3-(4-((5-fluoro-2-met hoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide;

LOXO-305;

LY 3527727.

Chemical & Physical Properties

Appearance:White to off-white solid powder

Assay: NLT99%

Boiling Point: 619.2 ℃

Density:1.44±0.1 g/cm3(Predicted)

Solubility :DMSO : 50 mg/mL (104.29 mM; Need ultrasonic)

Application:Pirtobrutinib, also known as LOXO-305 and LY 3527727, is a Bruton's tyrosine kinase (BTK) inhibitor and antineoplastic agent. Pirtobrutinib showed promising initial efficacy in pts with pretreated Richter transformation with extremely poor prognosis, including in patients who had received prior chemoimmunotherapy and covalent BTK inhibitors. Pirtobrutinib is a highly selective and potent non-covalent BTK inhibitor (BTKi) with high oral bioavailability and a long half-life, resulting in robust BTK target coverage even in high-grade malignancies with high BTK protein turnover.

Pirtobrutinib, a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations. Pirtobrutinib causes regression of BTK-dependent lymphoma tumors in mouse xenograft models. Pirtobrutinib is also more than 300-fold selective for BTK versus 370 other kinases tested and shows no significant inhibition of non-kinase off-targets at 1 μM.

We can also supply Pirtobrutinib intermediate:

4-[[(5-fluoro-2-metho xy-benzoyl)amino]methyl]benzoic acid CAS 1571888-11-3;

N-[[4-(2,2-dicyano-1-metho xy-vinyl)phenyl]methyl]-5-fluoro-2-metho xy-benzamide CAS 2764851-04-7;

[(1S)-2,2,2-tri-fluoro-1-methyl-ethyl]hydrazine CAS 2764851-02-5;

[(1S)-2,2,2-trifluoro-1-methylethyl]hydrazine hydrochloride CAS 2764851-03-6.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.